Avammune Therapeutics
Latest round
- Series A
Last raised
- May 2025
Total raised
- $12M
Investors
- 5
About Avammune Therapeutics
Based in the US, Avammune Therapeutics Inc.Founded in 2019 and headquartered in Philadelphia, US, Avammune Therapeutics Inc. focuses on creating innovative cancer therapies.Avammune Therapeutics specializes in the discovery and development of small molecule drug candidates that modulate the innate immune system, with a strong focus on oncology applications. The company's core products include AVA-NP-695, an orally available ENPP1 inhibitor demonstrating significant antitumor potency and potential to reduce tumor metastasis, and AVA-ADR-001, a first-in-class small molecule inhibitor of ADAR1 showing promising anti-tumor efficacy in preclinical models. These products aim to address unmet medical needs in cancer treatment by enhancing immune responses and improving patient outcomes with solid tumors.Avammune Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies involved in drug development. Revenue is derived from licensing agreements for AVA-NP-695 and AVA-ADR-001, which are positioned as key assets for clinical trials and commercialization. Transactions typically include milestone payments tied to the advancement of drug candidates through various development stages, as well as royalties on future sales once the products are on the market.In May 2025, Avammune Therapeutics Inc. The company plans to expand its pipeline of oral small molecule therapies and clinically develop its lead drug candidate.
Who invested in Avammune Therapeutics
5 investors across 1 round
See all investors in Avammune Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 7, 2025
Amount
$12M
Investors
Questions about Avammune Therapeutics
Who invested in Avammune Therapeutics?
Avammune Therapeutics has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Avammune Therapeutics raised?
Avammune Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Avammune Therapeutics last raise money?
Avammune Therapeutics's most recent round on record is a Series A, in May 2025.
What does Avammune Therapeutics do?
Based in the US, Avammune Therapeutics Inc.
Where is Avammune Therapeutics headquartered?
Avammune Therapeutics is headquartered in Philadelphia, US.
Which VCs invest in companies like Avammune Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Avammune Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Avammune Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.